Wall Street analysts predict that Evofem Biosciences, Inc. (NASDAQ:EVFM) will report sales of $1.70 million for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Evofem Biosciences' earnings, with the highest sales estimate coming in at $2.90 million and the lowest estimate coming in at $900,000.00. The business is scheduled to announce its next quarterly earnings results after the market closes on Thursday, March 4th.
According to Zacks, analysts expect that Evofem Biosciences will report full year sales of $1.79 million for the current year, with estimates ranging from $1.18 million to $3.10 million. For the next fiscal year, analysts expect that the firm will post sales of $41.96 million, with estimates ranging from $24.37 million to $62.40 million. Zacks' sales averages are an average based on a survey of research firms that that provide coverage for Evofem Biosciences.
Shares of EVFM opened at $4.20 on Thursday. The business's fifty day moving average price is $3.25 and its two-hundred day moving average price is $2.73. The firm has a market capitalization of $341.38 million, a price-to-earnings ratio of -2.15 and a beta of 0.07. Evofem Biosciences has a 52 week low of $1.91 and a 52 week high of $6.87.
A number of institutional investors have recently modified their holdings of EVFM. BlackRock Inc. raised its stake in Evofem Biosciences by 74.8% during the 3rd quarter. BlackRock Inc. now owns 4,953,929 shares of the biotechnology company's stock worth $11,691,000 after buying an additional 2,120,094 shares during the period. Heartland Advisors Inc. raised its stake in Evofem Biosciences by 10.9% during the 4th quarter. Heartland Advisors Inc. now owns 2,571,900 shares of the biotechnology company's stock worth $6,198,000 after buying an additional 252,250 shares during the period. State Street Corp raised its stake in Evofem Biosciences by 26.7% during the 3rd quarter. State Street Corp now owns 951,464 shares of the biotechnology company's stock worth $2,245,000 after buying an additional 200,570 shares during the period. GSA Capital Partners LLP raised its stake in Evofem Biosciences by 283.0% during the 4th quarter. GSA Capital Partners LLP now owns 255,303 shares of the biotechnology company's stock worth $615,000 after buying an additional 188,637 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in Evofem Biosciences by 548.8% during the 4th quarter. JPMorgan Chase & Co. now owns 211,822 shares of the biotechnology company's stock worth $510,000 after buying an additional 179,175 shares during the period. 44.84% of the stock is currently owned by institutional investors and hedge funds.
About Evofem Biosciences
Evofem Biosciences, Inc, a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, a vaginal pH regulator for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women.
See Also: How to Use a Moving Average for Trading
Get a free copy of the Zacks research report on Evofem Biosciences (EVFM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
8 Stocks That Robinhood Investors Got Right
The online investing app Robinhood has been a clear pandemic winner. As more Americans were forced to work from home, many made the decision to begin testing their investing skills by trading stocks. Robinhood appeals to millennial and/or novice investors for several reasons. First, the app makes it fun. You might say it “gamefies” stock trading. With commission-free trades, investors have an incentive to trade frequently. And many users of the app do just that.
The second reason is that it allows investors to buy partial (or fractional) shares. Although Robinhood is often associated with penny stocks, the app lets investors buy shares of “pricey” stocks like Tesla (NASDAQ:TSLA) without having to pay for a full share right away.
And data shows that Robinhood investors have a healthier risk appetite than other investors. And that appetite has increased since the start of the pandemic. This lines up to the time when investors had more time on their hands.
With that said, many Robinhood investors have been, quite frankly, using the app to engage in a legal form of gambling. I say this because trying to dive quickly in and out of the market in an attempt to capture a profit may work. But historically, it’s a path to ruin.
However there are two sides to every story. And the same is true of Robinhood investors. There are many examples of where these investors have gotten it right. In this presentation, we’ll show you eight examples of stocks that the market and Robinhood investors have gotten exactly right.
View the "8 Stocks That Robinhood Investors Got Right".